Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is set to issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of $2.53 per share for the quarter. Jazz Pharmaceuticals PLC has set its FY17 guidance at $10.70-11.30 EPS.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company had revenue of $394.39 million during the quarter, compared to analyst estimates of $410.83 million. During the same quarter in the previous year, the firm earned $2.67 earnings per share. The business’s revenue was up 3.5% on a year-over-year basis. On average, analysts expect Jazz Pharmaceuticals PLC to post $9.52 EPS for the current fiscal year and $11.36 EPS for the next fiscal year.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up 3.488% during trading on Tuesday, reaching $141.065. The company’s stock had a trading volume of 318,861 shares. The stock has a market capitalization of $8.47 billion, a price-to-earnings ratio of 21.729 and a beta of 1.05. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The company’s 50-day moving average price is $145.95 and its 200 day moving average price is $150.86.

A number of analysts recently weighed in on JAZZ shares. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 30th. Cantor Fitzgerald reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, August 29th. Mizuho cut shares of Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and lowered their target price for the company from $162.00 to $150.00 in a research note on Tuesday, July 4th. Deutsche Bank AG set a $178.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Wells Fargo & Company reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, August 29th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $180.88.

COPYRIGHT VIOLATION WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Set to Announce Quarterly Earnings on Tuesday” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/31/jazz-pharmaceuticals-plc-jazz-set-to-announce-quarterly-earnings-on-tuesday.html.

In related news, Director Paul L. Berns sold 662 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $142.37, for a total value of $94,248.94. Following the transaction, the director now directly owns 6,599 shares in the company, valued at $939,499.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Paul Treacy sold 1,304 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $143.32, for a total transaction of $186,889.28. The disclosure for this sale can be found here. Insiders have sold 4,517 shares of company stock worth $665,623 over the last three months. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Earnings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.